Iovance Biotherapeutics, Inc. (IOVA)
NASDAQ: IOVA · Real-Time Price · USD
4.270
+0.020 (0.47%)
Jun 29, 2026, 11:19 AM EDT - Market open
Iovance Biotherapeutics Stock Forecast
Stock Price Forecast
The 10 analysts with 12-month price forecasts for Iovance Biotherapeutics stock have an average target of 7.80, with a low estimate of 2.00 and a high estimate of 14. The average target predicts an increase of 82.67% from the current stock price of 4.27.
Analyst Consensus: Buy
Analyst Ratings
The average analyst rating for Iovance Biotherapeutics stock from 10 stock analysts is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.
Recommendation Trends
| Rating | Jan '26 | Feb '26 | Mar '26 | Apr '26 | May '26 | Jun '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 6 | 6 | 6 | 6 | 6 | 6 |
| Buy | 1 | 2 | 2 | 2 | 2 | 2 |
| Hold | 4 | 3 | 3 | 3 | 2 | 2 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 1 | 0 | 0 | 0 | 0 | 0 |
| Total | 12 | 11 | 11 | 11 | 10 | 10 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
Unknown Analyst Mizuho Securities No rating | Mizuho Securities | Buy Maintains $10 | Buy | Maintains | $10 | +134.19% | Jun 22, 2026 |
| H.C. Wainwright | H.C. Wainwright | Buy Reiterates $9 | Buy | Reiterates | $9 | +110.77% | Jun 4, 2026 |
| Barclays | Barclays | Buy Maintains $11 | Buy | Maintains | $11 | +157.61% | Jun 2, 2026 |
| Chardan Capital | Chardan Capital | Buy Reiterates $14 | Buy | Reiterates | $14 | +227.87% | May 8, 2026 |
| TD Cowen | TD Cowen | Buy Maintains $5 | Buy | Maintains | $5 | +17.10% | May 7, 2026 |
Financial Forecast
Revenue This Year
361.99M
from 263.50M
Increased by 37.38%
Revenue Next Year
496.28M
from 361.99M
Increased by 37.10%
EPS This Year
-0.56
from -1.09
EPS Next Year
-0.32
from -0.56
Revenue Forecast
| Revenue | 2026 | 2027 | 2028 |
|---|---|---|---|
| High | 369.8M | 543.7M | |
| Avg | 362.0M | 496.3M | |
| Low | 352.0M | 450.0M |
Revenue Growth
| Revenue Growth | 2026 | 2027 | 2028 |
|---|---|---|---|
| High | 40.3% | 50.2% | |
| Avg | 37.4% | 37.1% | |
| Low | 33.6% | 24.3% |
EPS Forecast
| EPS | 2026 | 2027 | 2028 |
|---|---|---|---|
| High | -0.46 | -0.23 | |
| Avg | -0.56 | -0.32 | |
| Low | -0.72 | -0.46 |
EPS Growth
| EPS Growth | 2026 | 2027 | 2028 |
|---|---|---|---|
| High | - | - | |
| Avg | - | - | |
| Low | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.